Tempest Therapeutics, Inc. Research and Development Expense
Tempest Therapeutics, Inc. (TPST) reported Research and Development Expense of $1.68 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2018-11-09
- Tempest Therapeutics, Inc. research and development expense for the quarter ending 2018-09-30 was $1.68M, a 58.17% decline year-over-year.
- Tempest Therapeutics, Inc. research and development expense for the quarter ending 2018-06-30 was $2.39M, a 52.09% decline year-over-year.
- Tempest Therapeutics, Inc. research and development expense for the quarter ending 2018-03-31 was $2.62M, a 54.53% decline year-over-year.
- Tempest Therapeutics, Inc. research and development expense for the quarter ending 2017-12-31 was $3.56M, a 24.40% decline year-over-year.
- Tempest Therapeutics, Inc. research and development expense for fiscal 2017 was $18.34M, a 15.27% decline from fiscal 2016.
- Tempest Therapeutics, Inc. research and development expense for fiscal 2016 was $21.64M, a 17.40% increase from fiscal 2015.
- Tempest Therapeutics, Inc. research and development expense for fiscal 2015 was $18.43M, a 15.38% decline from fiscal 2014.
- Tempest Therapeutics, Inc. research and development expense for fiscal 2014 was $21.78M, a 37.86% increase from fiscal 2013.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 15 month | Research and Development Expense 18 month | Research and Development Expense 21 month | Research and Development Expense 24 month | Research and Development Expense 27 month | Research and Development Expense 30 month | Research and Development Expense 33 month | Research and Development Expense 36 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-09-30 | $1.68M 10-Q · filed 2018-11-09 | $4.07M derived: sum of 2 quarters · filed 2018-11-09 | $6.70M 10-Q · filed 2018-11-09 | $10.26M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||
| 2018-06-30 | $2.39M 10-Q · filed 2018-08-09 | $5.01M 10-Q · filed 2018-08-09 | $8.57M derived: sum of 3 quarters · filed 2018-08-09 | $12.59M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||
| 2018-03-31 | $2.62M 10-Q · filed 2018-05-03 | $6.18M derived: sum of 2 quarters · filed 2018-05-03 | $10.20M derived: sum of 3 quarters · filed 2018-11-09 | $15.19M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||
| 2017-12-31 | $3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $7.58M derived: sum of 2 quarters · filed 2018-11-09 | $12.57M derived: sum of 3 quarters · filed 2018-11-09 | $18.34M 10-K · filed 2018-03-15 | ||||||||
| 2017-09-30 | $4.02M 10-Q · filed 2018-11-09 | $9.01M derived: sum of 2 quarters · filed 2018-11-09 | $14.78M 10-Q · filed 2018-11-09 | $19.49M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||
| 2017-06-30 | $5.00M 10-Q · filed 2018-08-09 | $10.76M 10-Q · filed 2018-08-09 | $15.47M derived: sum of 3 quarters · filed 2018-08-09 | $20.46M derived: sum of 4 quarters · filed 2018-08-09 | ||||||||
| 2017-03-31 | $5.76M 10-Q · filed 2018-05-03 | $10.47M derived: sum of 2 quarters · filed 2018-05-03 | $15.46M derived: sum of 3 quarters · filed 2018-05-03 | $21.45M derived: sum of 4 quarters · filed 2018-05-03 | ||||||||
| 2016-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $9.70M derived: sum of 2 quarters · filed 2018-03-15 | $15.69M derived: sum of 3 quarters · filed 2018-03-15 | $21.64M 10-K · filed 2018-03-15 | ||||||||
| 2016-09-30 | $4.99M 10-Q · filed 2017-11-02 | $10.98M derived: sum of 2 quarters · filed 2017-11-02 | $16.93M 10-Q · filed 2017-11-02 | $21.60M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||
| 2016-06-30 | $5.99M 10-Q · filed 2017-08-03 | $11.94M 10-Q · filed 2017-08-03 | $16.61M derived: sum of 3 quarters · filed 2018-03-15 | $20.61M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||
| 2016-03-31 | $5.96M 10-Q · filed 2017-05-09 | $10.62M derived: sum of 2 quarters · filed 2018-03-15 | $14.62M derived: sum of 3 quarters · filed 2018-03-15 | $18.64M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||
| 2015-12-31 | $4.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $8.66M derived: sum of 2 quarters · filed 2018-03-15 | $12.69M derived: sum of 3 quarters · filed 2018-03-15 | $18.43M 10-K · filed 2018-03-15 | ||||||||
| 2015-09-30 | $4.00M 10-Q · filed 2016-11-03 | $8.02M derived: sum of 2 quarters · filed 2016-11-03 | $13.77M 10-Q · filed 2016-11-03 | $21.04M derived: sum of 4 quarters · filed 2017-03-02 | ||||||||
| 2015-06-30 | $4.02M 10-Q · filed 2016-08-04 | $9.77M 10-Q · filed 2016-08-04 | $17.04M derived: sum of 3 quarters · filed 2017-03-02 | $22.37M derived: sum of 4 quarters · filed 2017-03-02 | ||||||||
| 2015-03-31 | $5.75M 10-Q · filed 2016-05-05 | $13.02M derived: sum of 2 quarters · filed 2017-03-02 | $18.34M derived: sum of 3 quarters · filed 2017-03-02 | $22.88M derived: sum of 4 quarters · filed 2017-03-02 | ||||||||
| 2014-12-31 | $7.27M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $12.60M derived: sum of 2 quarters · filed 2017-03-02 | $17.13M derived: sum of 3 quarters · filed 2017-03-02 | $21.78M 10-K · filed 2017-03-02 | ||||||||
| 2014-09-30 | $5.33M 10-Q · filed 2015-11-05 | $9.86M derived: sum of 2 quarters · filed 2015-11-05 | $14.51M 10-Q · filed 2015-11-05 | $21.80M derived: sum of 4 quarters · filed 2016-02-26 | ||||||||
| 2014-06-30 | $4.53M 10-Q · filed 2015-08-10 | $9.19M 10-Q · filed 2015-08-10 | $16.47M derived: sum of 3 quarters · filed 2016-02-26 | $19.73M derived: sum of 4 quarters · filed 2016-02-26 | ||||||||
| 2014-03-31 | $4.65M 10-Q · filed 2015-05-11 | $11.94M derived: sum of 2 quarters · filed 2016-02-26 | $15.20M derived: sum of 3 quarters · filed 2016-02-26 | $17.77M derived: sum of 4 quarters · filed 2016-02-26 | $27.95M 10-Q · filed 2014-05-08 | |||||||
| 2013-12-31 | $7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $10.55M derived: sum of 2 quarters · filed 2016-02-26 | $13.12M derived: sum of 3 quarters · filed 2016-02-26 | $15.80M 10-K · filed 2016-02-26 | $23.30M 10-K · filed 2014-02-27 | |||||||
| 2013-09-30 | $3.26M 10-Q · filed 2014-11-10 | $5.84M derived: sum of 2 quarters · filed 2014-11-10 | $8.52M 10-Q · filed 2014-11-10 | $10.95M derived: sum of 4 quarters · filed 2015-03-16 | $16.01M 10-Q · filed 2013-11-13 | |||||||
| 2013-06-30 | $2.58M 10-Q · filed 2014-08-07 | $5.26M 10-Q · filed 2014-08-07 | $7.69M derived: sum of 3 quarters · filed 2015-03-16 | $9.28M derived: sum of 4 quarters · filed 2015-03-16 | $12.75M 10-Q · filed 2013-08-13 | |||||||
| 2013-03-31 | $2.68M 10-Q · filed 2014-05-08 | $5.11M derived: sum of 2 quarters · filed 2015-03-16 | $6.71M derived: sum of 3 quarters · filed 2015-03-16 | $8.06M derived: sum of 4 quarters · filed 2015-03-16 | $10.17M 10-Q · filed 2013-05-15 | |||||||
| 2012-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $4.03M derived: sum of 2 quarters · filed 2015-03-16 | $5.38M derived: sum of 3 quarters · filed 2015-03-16 | $6.32M 10-K · filed 2015-03-16 | $7.49M 10-K · filed 2013-02-25 | |||||||
| 2012-09-30 | $1.59M 10-Q · filed 2013-11-13 | $2.95M derived: sum of 2 quarters · filed 2013-11-13 | $3.89M 10-Q · filed 2013-11-13 | $5.06M 10-Q · filed 2012-11-13 | ||||||||
| 2012-06-30 | $1.35M 10-Q · filed 2013-08-13 | $2.30M 10-Q · filed 2013-08-13 | $3.47M 10-Q · filed 2012-08-14 | |||||||||
| 2012-03-31 | $946.00K 10-Q · filed 2013-05-15 | |||||||||||
| 2011-12-31 | $1.17M 10-K · filed 2014-02-27 | |||||||||||
| 2011-09-30 | $404.00K 10-Q · filed 2012-11-13 | $404.00K 10-Q · filed 2012-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |